Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,406
datasets available to search
ShareScore release 0.9.0
Dataset results
1,406 results for “Migraine”
Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine
GEO Series GSE197289. Mus musculus; Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Data from: An fMRI-based neural marker for migraine without aura
Objective: To identify and validate a functional magnetic resonance imaging (fMRI)-based neural marker for migraine without aura (MwoA) and examine its association with treatment response. Methods: Cross-sectional studies with resting-state fMRI data from 230 participants and machine learning analyses were conducted. In Studies 1-3, we identified, cross-validated, independently validated, and cross-sectionally validated an fMRI-based neural marker for MwoA. In Study 4, we assessed the relationship between the neural marker and treatment responses in migraineurs who received a 4-week acupuncture treatment in a registered clinical trial. Results: In Study 1 (n = 116), we identified a neural marker with abnormal functional connectivity within the visual, default mode, sensorimotor, and frontal-parietal networks that could discriminate migraineurs from healthy controls (HCs) with 93% sensitivity and 89% specificity. In Study 2 (n = 38), we investigated the generalizability of the marker by applying it on an independent cohort of migraineurs and HCs and achieved 84% sensitivity and specificity. In Study 3 (n = 76), we verified the specificity of the marker with new datasets of migraineurs and other chronic pain disorders (chronic low back pain and fibromyalgia) and demonstrated 78% sensitivity and 76% specificity for discriminating migraineurs from non-migraineurs. In Study 4 (n = 116), we found that the changes in the marker responses showed significant correlation with the changes in headache frequency in response to real acupuncture. Conclusion: We identified an fMRI-based neural marker that captures distinct characteristics of MwoA and can link disease pattern changes to brain changes.
Supplemental material for: PROMISE-2: Efficacy and safety of eptinezumab in patients with chronic migraine
Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). Methods: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1–12. Results: Among treated participants (n = 1072), baseline mean MMDs was ~16.1 across groups. Treatment with eptinezumab 100 mg and 300 mg was associated with significant reductions in MMDs across weeks 1–12 compared with placebo (placebo, −5.6, 100 mg, −7.7, p < 0.0001 vs placebo; 300 mg, −8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab treated patients at an incidence of greater than 2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). Conclusion: In patients with CM, eptinezumab 100 mg and 300 mg was associated with a significant reduction in MMDs from the day following IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.
Data from: Large scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine
Objective: To identify a plasma metabolomic biomarker signature for migraine. Methods: Plasma samples from 8 Dutch cohorts (n = 10,153: 2,800 migraine patients and 7,353 controls) were profiled on a 1H-NMR-based metabolomics platform, to quantify 146 individual metabolites (e.g., lipids, fatty acids, and lipoproteins) and 79 metabolite ratios. Metabolite measures associated with migraine were obtained after single-metabolite logistic regression combined with a random-effects meta-analysis performed in a nonstratified and sex-stratified manner. Next, a global test analysis was performed to identify sets of related metabolites associated with migraine. The Holm procedure was applied to control the family-wise error rate at 5% in single-metabolite and global test analyses. Results: Decreases in the level of apolipoprotein A1 (β −0.10; 95% confidence interval [CI] −0.16, −0.05; adjusted p = 0.029) and free cholesterol to total lipid ratio present in small high-density lipoprotein subspecies (HDL) (β −0.10; 95% CI −0.15, −0.05; adjusted p = 0.029) were associated with migraine status. In addition, only in male participants, a decreased level of omega-3 fatty acids (β −0.24; 95% CI −0.36, −0.12; adjusted p = 0.033) was associated with migraine. Global test analysis further supported that HDL traits (but not other lipoproteins) were associated with migraine status. Conclusions: Metabolic profiling of plasma yielded alterations in HDL metabolism in migraine patients and decreased omega-3 fatty acids only in male migraineurs.
Data from: Abnormal thalamo-cortical network dynamics in migraine
Objective: To investigate the dynamic functional connectivity of thalamo-cortical networks in interictal migraine patients and whether clinical features are associated with abnormal connectivity. Methods: We investigated dynamic functional network connectivity (dFNC) of the migraine brain in 89 interictal migraine patients and 70 healthy controls. We focused on the temporal properties of thalamocortical connectivity using sliding window cross-correlation, clustering state analysis, and graph-theory methods. Relationships between clinical symptoms and abnormal dFNC were evaluated using a multivariate linear regression model. Results: Five dFNC brain states were identified to characterize and compare dynamic functional connectivity patterns. We demonstrated that migraineurs spent more time in a strongly interconnected between-network state, but they spent less time in a sparsely-connected state. Interestingly, we found that abnormal posterior thalamus (pulvinar nucleus) dFNC with the visual cortex and the precuneus were significantly correlated with headache frequency of migraine. Further topological measures revealed migraineurs had significantly lower efficiency of information transfer in both global and local dFNC. Conclusion: Our results demonstrated a transient pathological state with atypical thalamo-cortical connectivity in migraineurs and extended current findings regarding abnormal thalamo-cortical networks and dysrhythmia in migraine.
Figure 1 from: Abu-Zaid A, Abu-Zaid S, Barakat M, Al-Huniti R, Khair H (2024) Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e112909
Figure 1 Decrease in vestibular migraine symptom duration following supplementation (n = 57).
Figure 3 from: Abu-Zaid A, Abu-Zaid S, Barakat M, Al-Huniti R, Khair H (2024) Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e112909
Figure 3 Decrease in frequency of vestibular migraines following supplementation (n = 57).
Figure 2 from: Abu-Zaid A, Abu-Zaid S, Barakat M, Al-Huniti R, Khair H (2024) Effectiveness of combination therapy of magnesium, vitamin B2 and Co-enzyme 10 supplementation on vestibular migraine: a retrospective cohort study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e112909
Figure 2 Decrease in severity of vestibular migraine following supplementation (n = 57).
Dataset related to article:MULTIMODAL DIGITAL HEALTH TREATMENTS FOR CHRONIC MIGRAINE ASSOCIATED WITH MEDICATION OVERUSE HEADACHE: A LITERATURE APPRAISAL AND RESULTS OF A SINGLE‑ARM OPEN TRIAL (THE BE‑HOME PROGRAM)
<p><strong><span>Variables related to baseline, months 3, 6 and 12 referred to headache frequency, medication intake, GSE, HIT-6, BDI-II, MSQ and PCS, of patients with CM and MOH who participated to the BE-HOME trial.</span></strong></p>
Evaluation of a Wearable Device for Acute Treatment of Migraines
ClinicalTrials.gov study NCT07015125. IPD Sharing: NO. Countries: 1. Publications: 0.
Randomized Trial to Evaluate the Effectiveness of a Mindfulness Based Intervention (MBSR) for Patients Suffering From Migraine
ClinicalTrials.gov study NCT00826475. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines
ClinicalTrials.gov study NCT00690716. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine
ClinicalTrials.gov study NCT01578941. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Impact of a Nurse for Migraine Management: the IMPACT Project
ClinicalTrials.gov study NCT01804517. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SPG Block for Acute Pediatric Migraine
ClinicalTrials.gov study NCT03984045. IPD Sharing: NO. Countries: 1. Publications: 0.
Zonisamide for Fibromyalgia & Migraine
ClinicalTrials.gov study NCT00259636. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Investigation of Functional Brain Features in Women with Migraine
ClinicalTrials.gov study NCT06470958. IPD Sharing: NO. Countries: 1. Publications: 0.
Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines
ClinicalTrials.gov study NCT00727974. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis
ClinicalTrials.gov study NCT03190044. IPD Sharing: NO. Countries: 1. Publications: 0.
Abortive Effect of an Ear Insufflator on Migraine
ClinicalTrials.gov study NCT02614378. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.